Clinical value Leverage Daxor's FDA-cleared Blood Volume Analysis to offer precise fluid management insights that can reduce hospital length of stay and readmissions for heart failure and ICU patients, creating a compelling value proposition for hospitals and health systems focused on value-based care.

Expansion potential Target expansion opportunities around the new BVA program launches and portable next-generation analyzer demonstrations at cardiology facilities and major conferences to drive pilot deployments and contract-based adoption.

Market positioning Position Daxor as a specialized, FDA-cleared, ISO-13485 certified provider of real-time blood volume data with a focus on inpatient and ICU settings, differentiating from broader lab tests and competing Capillary Leak indexes.

Strategic partnerships Pursue collaborations with cardiovascular centers, SCCM-affiliated intensive care networks, and MedAxiom members to accelerate clinical data generation, case studies, and reimbursement pathways for BVA technology.

Clinical outcomes Highlight demonstrated improvements in patient outcomes and reduced readmissions from recent conference data to build ROI cases for health systems, funding bodies, and managed care organizations evaluating value-based solutions.